GHRH (1-44)

What it is

GHRH(1-44) is the full-length endogenous 44-amino-acid neuropeptide produced by neurons of the hypothalamic arcuate nucleus that drives the somatotroph axis. It is the canonical physiological stimulus for pulsatile growth hormone (GH) release from anterior pituitary somatotrophs. The shorter synthetic fragment GHRH(1-29) (sermorelin) retains full agonist activity; this page covers the native 44-aa form (see also our page on GHRH (1-29) for the clinical analog). GHRH binds the pituitary-type GHRH receptor (GHRHR), a Gs-coupled GPCR expressed on somatotrophs and, via splice variant SV1, on numerous extrapituitary and tumor tissues. Receptor engagement activates Gα(s), elevates intracellular cAMP, and engages PKA and downstream cascades including PI3K/AKT, ERK1/2, and CREB-mediated transcription of GH gene targets. In somatotrophs, the cAMP/PKA cascade opens voltage-gated calcium channels, triggering GH secretion vesicle fusion. Beyond the pituitary, GHRH exerts direct extrapituitary actions. In cardiac tissue, GHRH(1-44)NH₂ acts through Gα(s)/cAMP/PKA signaling to block the Gq/PLC-β/PKC-ε/calcineurin hypertrophy cascade in cardiomyocytes, positioning it as an endogenous antihypertrophic regulator. In neural tissues, GHRH activates cAMP/PKA/CREB and PI3K/Akt pathways, enhances neuronal survival, reduces tau phosphorylation, and suppresses NF-κB-mediated neuroinflammation. In pancreatic beta-cells, GHRH and its analogs enhance cell survival, supporting beta-cell mass preservation in diabetes models. GH secretion is modulated by the interplay of GHRH (stimulatory), somatostatin (inhibitory), and ghrelin (synergistic with GHRH), with additional modulation by leptin, nesfatin, klotho, thyroid hormones, sex steroids, and metabolic substrates such as glucose and free fatty acids. Critically, pulsatile GH release depends on the alternating phases of GHRH stimulation and somatostatin withdrawal rather than continuous GHRH exposure. The GHRH(1-44) full-length form and GHRH(1-29) analogs such as tesamorelin have been used in research to probe this axis; tesamorelin at 2 mg SC daily for two weeks significantly increased overnight mean GH pulses (p=0.004) and IGF-I by ~181 µg/L (p<0.0001) without impairing insulin sensitivity in healthy men.

Class: Endogenous hypothalamic neuropeptide / GH secretagogue — full-length 44-amino-acid growth hormone-releasing hormone

What it's studied for

• Stimulation of pituitary GH secretion and somatotroph axis regulation Mixed
  • Comprehensive narrative review of GH regulation in humans. Confirms GHRH as the primary hypothalamic GH secretagogue acting through GHRHR/cAMP/PKA; documents integration of >10 modulatory systems including somatostatin, ghrelin, leptin, and metabolic substrates in determining GH pulse amplitude and frequency. PMID 39579280 Bioletto F et al. Rev Endocr Metab Disord. 2025.
  • Phase II–style clinical study (n=13 healthy men, mean age 45, BMI 27.3). Tesamorelin (GHRH analog) 2 mg SC once daily for 2 weeks: overnight mean GH significantly increased (p=0.004), GH pulse area increased (p=0.001), IGF-I rose by ~181 µg/L (p<0.0001). Fasting glucose and insulin-stimulated glucose uptake were not si PMID 20943777 Stanley TL et al. J Clin Endocrinol Metab. 2011.
• Cardiac protection and anti-hypertrophic effects Animal studies only
  • In vitro: GHRH(1-44)NH₂ blocked phenylephrine-induced hypertrophy in cardiac cell lines and human iPSC-derived cardiomyocytes by inhibiting Gq/PLC-β/PKC-ε/calcineurin and activating Gα(s)/cAMP/PKA. In vivo: MR-409 (GHRH agonist) administered to transverse aortic constriction mice reduced cardiac hypertrophy, improved c PMID 29078377 Gesmundo I et al. Proc Natl Acad Sci USA. 2017.
• Neuroprotection and Alzheimer's disease — amyloid and neuroinflammation reduction Animal studies only
  • In vitro: GHRH(1-44)NH₂ enhanced neural stem cell survival and differentiation under amyloid-beta exposure via cAMP/PKA/CREB and PI3K/Akt; reduced tau phosphorylation and NF-κB neuroinflammation. In vivo: GHRH agonist MR-409 SC in 5xFAD Alzheimer's model mice reduced amyloid plaques, tau phosphorylation, gliosis, and p PMID 41946684 Pedrolli F et al. Cell Death Dis. 2026.
• Metabolic disease — pancreatic beta-cell protection and diabetes Animal studies only
  • Review documents GHRH receptor expression in pancreatic beta-cells, intestine, adipose tissue, and liver. GHRH and its analogs enhance survival of insulin-producing beta-cells in vitro and in animal models. Authors propose GHRH agonists may support beta-cell mass preservation in transplantation and metabolic disease se PMID 39560873 Steenblock C et al. Rev Endocr Metab Disord. 2025.
• Oncology — GHRH antagonists for cancer (GHRH receptor on tumors) Animal studies only
  • Triple-negative breast cancer samples expressed GHRHR mRNA in 25% of cases and splice variant SV1 in 70%. In the HCC1806 cell line, GHRH(1-44)NH₂ stimulated growth; GHRH antagonist MZ-J-7-118 inhibited it via ERK-1/2 suppression. Authors propose an autocrine growth loop and GHRHR targeting as a therapeutic strategy. In PMID 18629632 Köster F et al. Breast Cancer Res Treat. 2009.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• GHRH analog tesamorelin (2 mg SC daily × 2 weeks) in healthy men (n=13): no significant change in fasting glucose or insulin-stimulated glucose uptake, indicating preserved insulin sensitivity at therapeutic doses. PMID 20943777
• GHRH agonist MR-409 in 5xFAD mouse model: therapeutic doses did not alter systemic GH or IGF-1 levels, suggesting possible dissociation of CNS effects from systemic growth-promoting effects in this model, though human translation is unknown. PMID 41946684
• Potential oncological risk: GHRHR (including splice variant SV1) is expressed in multiple cancer types including triple-negative breast cancer; exogenous GHRH agonists stimulated growth of GHRHR-expressing cancer cell lines in vitro. This is a theoretical risk for native GHRH(1-44) in individuals with GHRHR-expressing malignancies. PMID 18629632

Contraindications

• Active malignancy — GHRHR is expressed on multiple tumor types including triple-negative breast cancer; exogenous GHRH stimulated tumor cell growth in vitro, while GHRH antagonists are being investigated as anti-tumor agents. Use in patients with active cancer is not established and could theoretically promote GHRHR-expressing tumor growth. PMID 18629632
• No formal clinical contraindications established in reviewed literature for native GHRH(1-44) in humans, as no human clinical trial data exist for this specific form. Contraindications are extrapolated from analog literature (sermorelin, tesamorelin). PMID 39579280